This article is more than 5 years old. Information may no longer be current.

MiMedx releases AmnioFix Injectable

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MiMedx Group Inc. announced the launch of its newest tissue product, AmnioFix Injectable, at the American Academy of Orthopaedic Surgeons 2012 Annual Meeting in San Francisco.

According to a company press release, AmnioFix Injectable is an allograft composed of micronized amniotic tissue, which is processed to optimize surgical performance and ease of use. The company’s proprietary Purion process retains the amniotic growth factors and cytokines inherent in and unique to placental tissue, resulting in an injectable tissue that offers a natural ability to reduce inflammation at the injection site and enhance soft tissue healing. AmnioFix has a 5-year shelf-life.